SCHEMBL349314

SCHEMBL349314

O=C(O)CCc1ccc(Cl)cc1

nearest known ligand 0.71

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 10/20 0.71
KEAP1 Q14145 1/20 0.64
MAP4K4 O95819 1/20 0.55
FFAR4 Q5NUL3 2/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
PDPK1 O15530 1/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
PLAAT3 P53816 3/20 0.53
PLAAT5 Q96KN8 3/20 0.53
PLAAT2 Q9NWW9 3/20 0.53
PLAAT4 Q9UL19 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11045221 0.98 FFAR1 (0.69) FFAR1KEAP1MAP4K4FFAR4CA1
Alcohol SCHEMBL7860672 0.92 FFAR1 (0.63) FFAR1KEAP1MAP4K4FFAR4CA1
Guanidine SCHEMBL5348315 0.90 FFAR1 (0.61) FFAR1KEAP1MAP4K4FFAR4CA1
SCHEMBL4985570 0.89 FFAR1 (0.59) FFAR1KEAP1MAP4K4FFAR4CA1
SCHEMBL69746 0.88 FFAR1 (0.81) FFAR1KEAP1FFAR4CA1CA2
SCHEMBL1570239 0.87 HDAC3 (0.67) FFAR1PLAAT3PLAAT5PLAAT2PLAAT4
Hydrochloric Acid SCHEMBL25264643 0.85 FFAR1 (0.77) FFAR1KEAP1FFAR4CA1CA2
SCHEMBL27670746 0.85 HDAC3 (0.64) FFAR1PLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL2418582 0.85 LTB4R (0.66) FFAR1FFAR4PLAAT3PLAAT5PLAAT2
SCHEMBL11239667 0.84 FFAR1 (1.00) FFAR1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 774 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120137643-A Composite material, preparation method thereof, photoelectric device and display device 广东聚华新型显示研究院 2025-06-13 CN claimed
US-12304894-B2 Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2025-05-20 US claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 CN claimed
WO-2024084379-A1 A NOVEL PROCESS FOR THE PREPARATION OF AMORPHOUS SOLID DISPERSION OF 1-{3-[3-(4-CHLOROPHENYL) PROPOXY] PROPYL} PIPERIDINE, HYDROCHLORIDE WITH HYDROXYPROPYL BETA-CYCLODEXTRIN (HPβCD) BIOPHORE INDIA PHARMACEUTICALS PVT. LTD (IN) 2024-04-25 WO claimed
US-11945788-B2 Process for preparing pitolisant hydrochloride and solid-state forms thereof NURAY CHEMICALS PRIVATE LIMITED (IN) 2024-04-02 US claimed
US-20230219914-A1 PROCESS FOR PREPARING PITOLISANT HYDROCHLORIDE AND SOLID-STATE FORMS THEREOF Nuray Chemicals Private Limiited (IN) 2023-07-13 US claimed
CN-114014825-B Synthesis method of histamine H3 receptor antagonist telithromycin 河南师范大学 2023-06-02 CN claimed
US-20220402886-A1 PROCESS FOR PREPARING PITOLISANT HYDROCHLORIDE AND SOLID-STATE FORMS THEREOF Nuray Chemicals Private Lmiited (IN) 2022-12-22 US claimed
US-20220194909-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE (CL) 2022-06-23 US claimed
CN-114014825-A Efficient synthesis method of histamine H3 receptor antagonist teloprolofen 河南师范大学 2022-02-08 CN claimed
US-6503413-B2 Polyalkylene polysiloxane, buffering agent, aqueous carrier THE PROCTER & GAMBLE COMPANY 2003-01-07 US claimed
EP-1255806-A1 STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS THE PROCTER & GAMBLE COMPANY (US) 2002-11-13 EP claimed
US-20020011584-A1 Stable, aqueous compositions for treating surfaces, especially fabrics THE PROCTOR & GAMBLE COMPANY 2002-01-31 US claimed
US-20020010154-A1 Compositions comprising cyclodextrin THE PROCTER & GAMBLE COMPANY 2002-01-24 US claimed
WO-2001088076-A1 COMPOSITIONS COMPRISING CYCLODEXTRIN THE PROCTER & GAMBLE COMPANY (US) 2001-11-22 WO claimed
US-6289286-B1 Surface regeneration of biosensors and characterization of biomolecules associated therewith BIACORE AB (SE) 2001-09-11 US claimed
WO-2001060961-A1 STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS THE PROCTER & GAMBLE COMPANY (US) 2001-08-23 WO claimed
EP-1082607-A1 SURFACE REGENERATION OF BIOSENSORS Biacore AB (SE) 2001-03-14 EP claimed
WO-1999063333-A1 SURFACE REGENERATION OF BIOSENSORS BIACORE AB (SE) 1999-12-09 WO claimed
US-5663030-A A PHENYL OR NORBORNANE DERIVATIVE AS AN ADDITIVE TO REDUCE HEAT AND ENERGY REQUIRED TO FUSE THE TONER AND TO REDUCE JAMMING OF THE EQUIPMENT XEROX CORPORATION (US) 1997-09-02 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402886-A1 PROCESS FOR PREPARING PITOLISANT HYDROCHLORIDE AND SOLID-STATE FORMS THEREOF PITHD1, MLN, TPP1 FFAR1 871/4885KEAP1 1440/4885MAP4K4 3723/4885
US-20220194909-A1 DERIVATIVES OF ADAMANTYL OXADIAZOLES AND PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITION COMPRISING SAME, SYNTHESIS METHOD, SUITABLE FOR USE AS EFFECTIVE AND SELECTIVE INHIBITORS OF THE REDUCTASE ACTIVITY OF THE ENZYME 11-BETA DEHYDROGENASE TYPE 1 (11B-HSD1) HSD11B1, HSD11B2, CYP11B1 FFAR1 695/4885KEAP1 1504/4885MAP4K4 2731/4885
US-11945788-B2 Process for preparing pitolisant hydrochloride and solid-state forms thereof PITHD1, MLN, TPP1 FFAR1 871/4885KEAP1 1440/4885MAP4K4 3723/4885
US-20020010154-A1 Compositions comprising cyclodextrin FFAR4, FRG1, FGB FFAR1 4/4885KEAP1 4345/4885MAP4K4 2706/4885
US-20230219914-A1 PROCESS FOR PREPARING PITOLISANT HYDROCHLORIDE AND SOLID-STATE FORMS THEREOF PITHD1, MLN, TPP1 FFAR1 871/4885KEAP1 1440/4885MAP4K4 3723/4885
US-12304894-B2 Derivatives of adamantyl oxadiazoles and pharmaceutically acceptable solvates, hydrates and salts thereof, pharmaceutical composition comprising same, synthesis method, suitable for use as effective and selective inhibitors of the reductase activity of the enzyme 11-beta dehydrogenase type 1 (11β-HSD1) HSD11B1, HSD11B2, HSD17B1 FFAR1 623/4885KEAP1 1272/4885MAP4K4 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.